[go: up one dir, main page]

Schrijvers et al., 2011 - Google Patents

Biomarker profiles for Alzheimer disease: diagnosing disease or establishing health?

Schrijvers et al., 2011

View PDF
Document ID
5000156976036058058
Author
Schrijvers E
Hofman A
Koudstaal P
Breteler M
Publication year
Publication venue
Biomarkers and Risk Factors of Dementia

External Links

Snippet

Background: The approach to biomarker discovery and evaluation lacks standard guidelines. An inappropriate selection of study cases and controls can bias the performance of a diagnostic test. We illustrate the impact of different control selections in the evaluation of …
Continue reading at pure.eur.nl (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345—Medical expert systems, neural networks or other automated diagnosis

Similar Documents

Publication Publication Date Title
Van Hulle et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
JP7102487B2 (en) Blood-based screening to detect neurological disorders in primary care settings
Zhao et al. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer’s dementia
Forlenza et al. Cerebrospinal fluid biomarkers in Alzheimer's disease: diagnostic accuracy and prediction of dementia
Wang et al. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease
Sun et al. Olfactory identification testing as a predictor of the development of Alzheimer's dementia: a systematic review
AU2014354808A1 (en) Personalized medicine approach for treating cognitive loss
Lutz et al. A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease
Cousins et al. ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration
Pagonabarraga et al. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Tropea et al. Plasma phosphorylated tau181 predicts cognitive and functional decline
Weintraub et al. ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods
CN115461474A (en) Protein markers for assessing alzheimer's disease
CN105705652A (en) Method for aiding differential diagnosis of stroke
Öhrfelt et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease
US8753607B2 (en) Methods and kits for the differential diagnosis of Alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia, comprising FAS-L and CK 18 as biomarkers
Sewell et al. Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits
Shen et al. Systematic proteomics in Autosomal dominant Alzheimer’s disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathways
Kubota et al. Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort
Edwards et al. Molecular markers of neuropsychological functioning and Alzheimer's disease
Schjønning Nielsen et al. Are CSF biomarkers useful as prognostic indicators in diagnostically unresolved cognitively impaired patients in a normal clinical setting
Schrijvers et al. Biomarker profiles for Alzheimer disease: diagnosing disease or establishing health?
WO2007139777A2 (en) Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
Pahlke et al. Blood‐based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta‐analysis
Cousins et al. Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction